Deciphera Pharmaceuticals LLC Valuation

Deciphera Pharmaceuticals Investor Information

About 28.0% of the company shares are held by company insiders. The company recorded a loss per share of 2.21. Deciphera Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Deciphera Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Deciphera Pharmaceuticals LLC is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.

Deciphera Pharmaceuticals Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Deciphera Pharmaceuticals has an asset utilization ratio of 34.49 percent. This signifies that the Company is making $0.34 for each dollar of assets. An increasing asset utilization means that Deciphera Pharmaceuticals LLC is more efficient with each dollar of assets it utilizes for everyday operations.

Deciphera Pharmaceuticals Ownership Allocation

Deciphera Pharmaceuticals holds a total of 86.48 Million outstanding shares. The majority of Deciphera Pharmaceuticals LLC outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Deciphera Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Deciphera Pharmaceuticals. Please pay attention to any change in the institutional holdings of Deciphera Pharmaceuticals LLC as this could imply that something significant has changed or is about to change at the company. Also note that almost four hundred fourty-one thousand twenty-eight invesors are currently shorting Deciphera Pharmaceuticals expressing very little confidence in its future performance.

Deciphera Pharmaceuticals Profitability Analysis

The company reported the previous year's revenue of 163.36 M. Net Loss for the year was (194.94 M) with loss before overhead, payroll, taxes, and interest of (62.55 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

If you are still planning to invest in Deciphera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Deciphera Pharmaceuticals' history and understand the potential risks before investing.